3D printed furosemide and sildenafil tablets: Innovative production and quality control

Three-dimensional (3D) printing of pharmaceuticals has the potential to revolutionise personalised medicine but is as yet largely unexplored. A proof-of-concept study a novel heated, piston-driven semi-solid extrusion 3D printer was performed by producing furosemide and sildenafil tablets for paediatric patients. The average weight 141.1 mg (RSD 1.26%). acceptance values content uniformity were 4.2–10.6 (concentration RSD 0.41–0.63%), 4.8–8.9 0.76–0.97%) 6.6–9.2 0.94–1.44%) 2 mg, 10 4 respectively. dissolution rate limiting step dissolving eroding tablet matrix showed an immediate release. complied requirements European Pharmacopoeia (EP) mass (EP 2.9.5), 2.9.40) conventional release 2.9.3). While they complied, not all these quality tests might be suitable printed due layering small batch production. To assess adequate layer adhesion adjusted friability 2.9.7) resistance crushing 2.9.8) are proposed.